ICD-10-CM Diagnosis Code Z15.89 ICD-10-CM Diagnosis Code Z15.09 Susceptibility to disease, genetic Z15.89 ICD-10-CM Diagnosis Code Z15.89 ICD-10-CM Diagnosis Code Z15.09 Li-Fraumeni Z15.01 ICD-10-CM Codes Adjacent To Z15.01 Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
2018/2019 ICD-10-CM Diagnosis Code D68.52. Prothrombin gene mutation. 2016 2017 2018 2019 Billable/Specific Code. D68.52 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
2018/2019 ICD-10-CM Diagnosis Code D68.2. Hereditary deficiency of other clotting factors. 2016 2017 2018 2019 Billable/Specific Code. D68.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Genetic susceptibility to malignant neoplasm of breast. Z15.01 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM Z15.01 became effective on October 1, 2018.
Prothrombin gene mutation (or Factor II mutation or Prothrombin G20210A) is an inherited condition that increases your predisposition to develop abnormal blood clots in the veins (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE).
This test measures how much of a protein called factor II is in your blood. Factor II is also called prothrombin. This test can help find out whether you have a bleeding or blood clotting disorder.
BRCA1 and/or 2 positive results are assigned either ICD-10-CM code Z15. 01 Genetic susceptibility to malignant neoplasm of breast or Z15. 02 Genetic susceptibility to malignant neoplasm of ovary, depending on family history.
A change in the prothrombin gene is present in 2-4% (or 1 in 50 to 1 in 25) of Caucasians, and is more common in individuals of European ancestry. In the United States, approximately 0.4% (about 1 in 250) of African Americans also have the mutation.
The Factor V variant known as Factor V Leiden (or rs6025) is associated with an approximately 300% increased risk in heterozygotes and an up to 8000% increased risk in homozygotes. The Factor II rs1799963 polymorphism (or G20210A) may also independently increase the risk by approximately 200%.
Diagnosis of factor II deficiency is based on your medical history, any family history of bleeding problems, and lab tests. Lab tests for bleeding disorders include: Factor assays: These tests check the performance of specific factors to identify missing or poorly performing factors.
Chromosomal abnormality, unspecified Q99. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Q99. 9 became effective on October 1, 2021.
39 (Encounter for other screening for malignant neoplasm of breast). Z12. 39 is the correct code to use when employing any other breast cancer screening technique (besides mammogram) and is generally used with breast MRIs.
Listen to pronunciation. (… NEH-guh-tiv) Describes cells that have a small amount or none of a protein called HER2 on their surface.
The incidence is estimated at 1 in 2 million in the general population.
Factor II (prothrombin): Synthesized in the liver; becomes active only after carboxylation by vitamin K. It is converted to thrombin (factor IIa).
Hypoprothrombinemia; Factor II deficiency; Dysprothrombinemia. Prothrombin deficiency is a disorder caused by a lack of a protein in the blood called prothrombin. It leads to problems with blood clotting (coagulation). Prothrombin is also known as factor II (factor two).